首页> 外文期刊>American journal of therapeutics >Vesnarinone-mediated alterations of gene expression in cardiac fibroblasts from aortic regurgitant hearts.
【24h】

Vesnarinone-mediated alterations of gene expression in cardiac fibroblasts from aortic regurgitant hearts.

机译:Vesnarinone介导的来自主动脉反流心脏的心脏成纤维细胞中基因表达的改变。

获取原文
获取原文并翻译 | 示例
           

摘要

Pathologic fibrosis precedes heart failure (CHF) and death in experimental aortic regurgitation (AR). Vesnarinone, a positively inotropic quinolone derivative, suppresses survival of fibroblasts (CF) from hearts with chronic experimental AR. To explore further the potential effects of vesnarinone on cardiac fibrosis in AR, we tested the hypothesis that vesnarinone suppresses gene expression induced by AR in CF. Differentially expressed genes were isolated by suppression subtractive hybridization (SSH) in CF from hearts of 2 New Zealand White rabbits with surgically induced AR compared with 2 normal rabbits. In cultured AR-CF treated with and without vesnarinone (4 doses, including the dose that had caused maximal survival suppression in cultured AR-CF), drug effect was assessed on expression of genes found to be up-regulated by AR. SSH, reverse Northern analysis, and Northern analysis indicated that at doses several orders of magnitude lower than those used for treatment in CHF vesnarinone significantly down-regulated 2 genes (thrombospondin 1, annexin II) up-regulated by AR. The study confirmed earlier findings of AR-mediated alteration in expression of genes that code for noncollagen extracellular matrix (ECM) proteins. Thus, in CF conditioned by exposure to AR, vesnarinone at relatively low doses suppresses genes coding for 2 noncollagen ECM proteins up-regulated by AR. These pharmacologic effects may underlie potentially therapeutic mitigation of fibrosis by vesnarinone.
机译:病理性纤维化先于心力衰竭(CHF)和实验性主动脉瓣反流(AR)死亡。 Vesnarinone是一种正性肌力喹诺酮衍生物,可抑制患有慢性实验性AR的心脏成纤维细胞(CF)的存活。为了进一步探讨维纳利酮对AR心脏纤维化的潜在影响,我们测试了维纳利酮抑制CF中AR诱导的基因表达的假说。与2只正常兔相比,通过抑制消减杂交(SSH)在CF中从2只具有手术诱发的AR的新西兰白兔的心脏中分离了差异表达的基因。在使用和不使用维那利酮治疗的培养AR-CF(4剂,包括在培养的AR-CF中引起最大生存抑制的剂量)中,评估发现AR上调的基因表达具有药物作用。 SSH,反向Northern分析和Northern分析表明,剂量比CHF维纳利酮治疗所用剂量低几个数量级,从而显着下调了AR上调的2个基因(血小板反应蛋白1,膜联蛋白II)。这项研究证实了AR介导的编码非胶原细胞外基质(ECM)蛋白的基因表达变化的早期发现。因此,在通过暴露于AR而调节的CF中,相对较低剂量的维纳利酮可抑制编码由AR上调的2种非胶原ECM蛋白的基因。这些药理作用可能是维那利酮可减轻纤维化的潜在治疗基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号